Safety Alerts & Recalls
What does this mean?
If you are currently receiving Avastin as treatment for metastatic breast cancer, please speak to your oncologist about this new FDA action. Your oncologist can review your treatment options with you and also use their medical judgment when deciding whether you should continue treatment with Avastin or consider other therapeutic options.
If you have other questions or concerns about Avastin, please follow up with your oncologist or other healthcare professional treating your cancer.
FDA Begins Process To Remove Breast Cancer Indication From Avastin Prescribing Information Label
The U.S. Food and Drug Administration (FDA) announced today that the agency is recommending removing the breast cancer indication from the label for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use. After reviewing of all available data relating to the use of Avastin to treat metastatic breast cancer, the FDA has determined that the risks of the drug outweigh the benefits for this use.
Avastin is also approved for treatment of advanced colon, lung, kidney, and brain cancers. Today's action does not affect the use of Avastin for these types of cancers.
To view the FDA webpage titled "Question and Answers about Avastin", please visit
For more information, please visit: more information here